drugset / Trial / NCT00975143

Efficacy and Safety of CIP-Isotretinoin in Patients With Severe Recalcitrant Nodular Acne

NCT00975143

Phase 3 Completed 925 enrolled Cipher Pharmaceuticals Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to compare the efficacy and safety of CIP-Isotretinoin and a marketed (generic) formulation of isotretinoin when both are administered twice daily with meals.

Timeline

Start
2009-09
Primary completion
2011-05
Completion
2011-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Isotretinoin Other / unclassified 1 mg/kg Oral

Indications